You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 134 No. 11, November 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  The Cutting Edge: Challenges in Medical and Surgical Therapeutics
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (11)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Dermatology, Other
 •Hematology/ Hematologic Malignancies
 •Leukemias/ Lymphomas
 •Immunologic Disorders
 •Alert me on articles by topic

Intralesional Cisplatin for the Treatment of Cutaneous B-Cell Lymphoma

Werner Kempf, MD; Reinhardn Dummer, MD; Monika Hess Schmid, MD; Tanja Fritz, MD; Brunello Wüthrich, MD; Guenter Burg, MD
Department of Dermatology, Zurich University Hospital, Zurich, Switzerland

Arch Dermatol. 1998;134:1343-1345.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

REPORT OF A CASE

A 56-year-old white woman presented with a solid erythematous nodule on her scalp that had developed 6 years earlier. She denied having a fever, losing weight, or sweating during the night. Her medical history was notable for epilepsy, which was adequately controlled with phenothiazine and chlorpromazine therapy. When a solitary nodule first appeared on the patient's head 6 years earlier, a biopsy specimen revealed nodular, dense B-cell infiltrates without blasts, nuclear atypias, or mitoses. Therefore, the lesion had been regarded clinically and histologically as a B-cell pseudolymphoma. The patient was subsequently treated with potent topical corticosteroid creams and local psoralen–UV-A, but within 2 years the preexisting nodule became larger and 2 further nodules appeared despite the therapy. After topical chemotherapy using carbomustine and topical corticosteroids, the patient had a partial response . . . [Full Text of this Article]

THERAPEUTIC CHALLENGE

SOLUTION

COMMENT



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas
Senff et al.
Blood 2008;112:1600-1609.
ABSTRACT | FULL TEXT  

The Role of Intratumoral Therapy With Cisplatin/Epinephrine Injectable Gel in the Management of Advanced Squamous Cell Carcinoma of the Head and Neck
Wenig et al.
Arch Otolaryngol Head Neck Surg 2002;128:880-885.
ABSTRACT | FULL TEXT  

Intralesional Therapy With Anti-CD20 Monoclonal Antibody Rituximab in Primary Cutaneous B-Cell Lymphoma
Heinzerling et al.
Arch Dermatol 2000;136:374-378.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.